antivir
screen
purpos
infect
cell
cultur
viru
studi
ideal
result
induct
within
day
nearli
complet
cpe
allow
calcul
accept
z
factor
human
corona
viru
caus
limit
cpe
differ
cell
line
schildgen
et
al
follow
infect
cell
virusinduc
cpe
low
allow
readout
base
classic
colorimetr
method
mt
assay
even
follow
prolong
incub
time
day
develop
antivir
screeningsassay
explor
whether
deadcel
proteas
substrat
could
use
instead
substrat
use
quench
peptid
releas
fluorophor
upon
proteolyticcleavag
proteas
latter
releas
dead
cell
follow
differ
round
optim
screen
protocol
develop
cell
plate
format
infect
moi
l
cell
cultur
cellsml
imdm
fb
medium
cultur
subsequ
incub
day
c
l
peptid
solut
ad
fluoresc
quantit
hr
incub
c
roughli
increas
fluoresc
intens
infect
cultur
observ
compar
uninfect
cultur
low
welltowel
variabl
z
factor
calcul
differ
experi
rang
indic
excel
assay
qualiti
polyclon
antiserum
prevent
coronaviru
infect
cell
cultur
use
posit
control
allow
valid
assay
antivir
screen
purpos
conclus
condit
viabil
stain
inadequ
quantit
virusinduc
cpe
novel
simpl
conveni
method
detect
celldeath
suitabl
highthroughput
screen
purpos
employ
viral
infect
remain
major
burden
human
health
worldwid
difficult
estim
total
number
diseas
caus
viral
infect
mortal
caus
specif
viral
pathogen
well
describ
today
antivir
drug
avail
treatment
infect
hiv
ii
dna
virus
herp
virus
hepat
b
viru
poxvirus
iii
small
number
rna
virus
hcv
rsv
influenza
viru
decad
rigor
effort
need
develop
drug
specif
therapi
still
lack
treatment
infect
rna
virus
leav
support
care
option
major
strategi
identifi
novel
antivir
screen
compound
librari
use
phenotyp
assay
diseas
area
contribut
phenotyp
screen
discoveri
firstinclass
smallmolecul
drug
exce
targetbas
approach
swinney
anthoni
main
phenotyp
use
antivir
assay
develop
viru
induc
cythopath
effect
cpe
viru
infect
render
suffici
cpe
cell
cultur
standard
viabil
assay
ex
mt
reduct
feasibl
detect
viral
antivir
activ
howev
cpe
limit
complic
expens
tool
need
ex
atp
quantit
previous
method
report
quantifi
cell
toxic
method
use
deadcel
proteas
substrat
contain
fluorophor
quench
coval
linkag
two
alaalaph
peptid
method
use
detect
cell
death
sinc
proteolyticcleavag
proteas
releas
dead
cell
restor
fluorophor
nile
et
al
fig
method
develop
quantit
limit
cpe
readout
homogen
rather
inexpens
therefor
amend
mediumor
highthroughput
screen
campaign
paper
method
describ
solut
screen
inhibitor
human
coronaviru
human
coronaviru
use
model
system
sinc
use
cellular
receptor
sarsviru
caus
limit
cpe
differ
cell
line
schildgen
et
al
make
cpe
quantit
troublesom
classic
viabil
stain
ex
mt
reduct
peptid
purchas
eurogentec
belgium
human
coronaviru
strain
cell
line
kindli
provid
ron
fouchier
erasmu
medic
center
rotterdam
netherland
strain
isol
month
old
boy
suffer
pneumonia
cell
subclon
verowho
cell
kuiken
et
al
cultur
iscov
modifi
dulbecco
medium
life
technolog
gent
belgiumcat
fb
iu
penicillinml
g
streptomycinml
cell
split
twice
weekli
igg
polyclon
goat
igg
control
obtain
r
system
abingdon
unit
kingdom
cat
solubil
dpb
mgml
store
c
use
differ
round
optim
follow
antivir
protocol
develop
cell
plate
format
infect
moi
l
cell
cultur
cellswel
imdm
fb
medium
cultur
incub
subsequ
day
c
l
peptid
solut
final
concentr
ad
fluoresc
measur
h
incub
c
use
paramet
rhodamin
fluoresc
readout
mt
inner
salt
reduct
assay
mtsphenazin
methosulph
pm
stock
solut
mgml
mt
promega
leiden
netherland
gml
pm
sigmaaldrich
bornem
belgium
pb
ph
dilut
mem
life
technolog
gent
belgium
cat
medium
aspir
well
l
mtspm
solut
ad
h
incub
c
absorb
measur
nm
first
experi
viru
titrat
two
differ
virusstock
carri
day
pi
readout
perform
microscop
score
cpe
ii
use
cytotoxfluor
tm
cytotox
assay
promega
leiden
netherland
cat
cytotoxfluor
tm
assay
develop
quantit
celldeath
base
cleavag
peptid
proteas
releas
dead
cell
nile
et
al
experi
assay
use
accord
manufactur
instruct
result
present
fig
virusstock
good
correl
observ
level
cpe
increas
level
fluoresc
observ
indic
releas
proteas
cultur
develop
cpe
subsequ
cleavag
peptid
fluoresc
substrat
use
quantit
cpe
similar
experi
carri
use
method
detect
cell
viabil
mt
reduct
method
fig
quantit
ldh
releas
data
shown
signific
differ
infect
noninfect
cell
cultur
could
observ
next
experi
design
optim
assay
screen
purpos
optim
condit
obtain
cellswel
cell
infect
moi
ccid
cell
imdm
medium
supplement
fb
medium
upon
infect
cultur
maintain
day
c
l
peptid
solut
final
concentr
ad
fluoresc
measur
hr
incub
c
use
paramet
rhodamin
fluoresc
readout
amount
peptid
use
condit
lower
propos
manufactur
cytotoxfluor
tm
assay
use
lower
level
peptid
result
decreas
signal
signaltonois
ratio
remain
suffici
high
use
screen
condit
see
main
reason
lower
amount
peptid
make
screen
campaign
afford
batch
peptid
prepar
commerci
supplier
peptid
mw
gmol
obtain
light
yellow
powder
puriti
determin
hplc
store
c
use
peptid
stock
solut
prepar
dmso
mm
store
c
use
subsequ
experi
perform
custom
synthes
peptid
stock
compar
uninfec
ted
infec
ted
uninfec
ted
infec
ted
fig
compar
mt
reduct
cleavag
infect
assay
carri
use
protocol
antivir
assay
describ
method
five
day
pi
cpe
quantit
use
either
mt
reduct
left
cleavag
cytotoxfluor
tm
assay
right
cleavag
assay
allow
quantit
limit
amount
cpe
cytotoxfluor
tm
kit
addit
antivir
activ
known
sar
inhibitor
igg
evalu
antibodi
inhibit
sar
viru
replic
bind
prevent
viru
enter
cell
li
et
al
iven
et
al
experi
setup
standard
antivir
experi
antibodi
dilut
medium
differ
concentr
duplic
viru
cell
ad
way
polyclon
goat
igg
use
control
untreat
infect
viru
control
treat
uninfect
cell
control
cultur
includ
plate
well
day
pi
one
plate
analyz
use
cytotoxfluor
tm
kit
accord
manufactur
protocol
except
peptid
use
lower
concentr
brief
peptid
solut
dilut
assay
buffer
suppli
kit
lwell
ad
plate
plate
analyz
parallel
use
custom
made
peptid
end
mm
dmso
stock
peptid
dilut
assay
medium
lwell
ad
final
peptid
concentr
plate
incub
c
follow
thorough
shake
plate
read
result
present
fig
perform
custom
prepar
peptid
batch
compar
cytotoxfluor
tm
kit
z
factor
calcul
experi
custom
prepar
commerci
peptid
respect
z
indic
suffici
qualiti
screen
zhang
et
al
addit
result
show
igg
inhibit
vitro
replic
ec
gml
polyclon
goat
igg
use
neg
control
show
ec
gml
fig
report
previous
igg
toxic
concentr
gml
li
et
al
iven
et
al
also
experi
effect
igg
cellular
morpholog
could
observ
microscop
data
shown
antivir
activ
found
pronounc
activ
sar
coronaviru
li
et
al
iven
et
al
unexpect
sinc
virus
known
bind
receptor
differ
evolv
independ
abil
use
cellular
entri
wu
et
al
final
two
independ
antivir
assay
carri
use
custom
prepar
peptid
assay
four
plate
use
well
plate
fluoresc
quantifi
day
pi
result
zfactor
fig
demonstr
method
previous
valid
quantit
cell
toxic
nile
et
al
also
use
quantit
viru
induc
cpe
antivir
activ
condit
suitabl
screen
assay
principl
reli
detect
proteas
releas
dead
cell
use
peptid
upon
cleavag
turn
fluoresc
main
advantag
method
comparison
cell
viabil
measur
mt
reduct
ldh
releas
method
sensit
detect
limit
viru
induc
cpe
allow
use
antivir
screen
campaign
virus
caus
limit
level
cpe
addit
assay
highli
homogen
wash
step
afford
hand
cost
substrat
anoth
advantag
nondestruct
natur
method
allow
microscop
inspect
simultan
sequenti
use
assay
method
well
exampl
evalu
toxic
antiprolif
effect
compound
method
nondestruct
sampl
remain
infecti
gener
limit
fluoresc
measur
plate
reader
plate
lid
cover
plate
